12 February 2021
Visiongain has published a new report on US PRP and Stem Cell Alopecia Treatment Market Report 2021-2031: Forecasts, by End User (Dermatology Clinics, Hospitals). PLUS Profiles of Leading Pharma Contract Manufacturing Companies and Regional and Leading National Market Analysis. PLUS COVID-19 Recovery Scenarios.
U.S. PRP and Stem Cell Alopecia Treatment market was valued at US$ xx billion in 2020 and is projected to reach at a market value of US$ xx billion by 2031. Increase in the number of people suffering from alopecia and growing awareness and acceptance of novel treatment techniques are some of the factors driving demand for these procedures.
Alopecia is a condition that causes hair to fall out in small areas, which can be unnoticeable. These patches may connect, however, and then become visible. Thisdisorder develops when the immune system outbreaks the hair follicles, resulting in hair loss.
Stem cell and platelet-rich plasma (PRP) therapies are considered as regenerative or biomedicines. They are minimally invasive and hence reduce the need for surgery. These therapies help arouse, rebuild, and strengthen hair regrowth, instead of removing damaged tissue from the scalp. Increasing inclination for minimally intrusive procedures over surgeries is expected to boost the U.S. market for PRP and Stem Cell Alopecia Treatment.
Novel therapies for alopecia are preferred by dermatologists and patients over conventional drugs such as corticosteroids. Greater preference for these therapies arises from efficient and faster hair regrowth as compared to other corticosteroid treatments. Additionally, ease of administration of these novel therapies is expected to drive demand over the forecast period.
The US is observing a huge growth in the number of people suffering from alopecia. This growth has in-turn boosted the demand for the growth in the PRP and Stem Cell treatment market for diagnostic patient suffering from alopecia in the US.
US PRP and Stem cell market is segmented on the basis of end user industry, the market has been further segmented into hospitals, dermatology clinics, and other centres. The dermatology clinic segment is expected to dominate the market during the forecast period.The growth in the clinic segment is growing owing to the specialized treatment and easy accessibility available at these clinics along-with the alternative of low cost treatment provided by these clinics in the US.
Most of the treatments in the U.S. are done by dermatologists in their privately owned establishment. For instance, according to the National Ambulatory Medical Care Survey (NAMCS) and National Hospital Ambulatory Medical Care Survey (NHAMCS), dermatologists treat 84.8 % of total alopecia patients in the U.S. This is paving the way for the segment a significant boost over the forecast period.
Some of the companies profiled in the report include; Orange County Hair Restoration Center, Hair Sciences Center of Colorado, Anderson Center for Hair, Evolution Hair Loss Institute, Savola Aesthetic Dermatology Center, PLC, Virginia Surgical Center, Hair Transplant Institute of Miami, and Colorado Surgical Center& Hair Institute.
The U.S. market for PRP and Stem Cell Alopecia Treatment consists of a large number of clinicsand institutes offering innovative alopecia treatment options such as PRP and stem cell therapies. Clinics providing these therapies are present across the country, with the highest number of treatments being carried out in dermatology clinics.
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to firstname.lastname@example.org or call her on +44 (0) 20 7549 9987.
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.
Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.
Global liposomal drug delivery devices market is projected to grow at a CAGR of 10.69% by 2032.
21 June 2022
The global nanotechnology in drug delivery market was valued at US$53.0 billion in 2021 and is projected to grow at a CAGR of 18.7% during the forecast period 2022-2032.
20 June 2022
The global respiratory drug delivery technologies market was valued at US$59.51 billion in 2022 and is projected to grow at a CAGR of 7.31% during the forecast period 2022-2032.
15 June 2022
The global artificial intelligence (AI) in drug discovery market was valued at US$791 million in 2021 and is projected to grow at a CAGR of 30.7% during the forecast period 2022-2032.